Avantor named best company for upstream processing & single-use solutions at BMK 2022

Awards recognize Avantor innovations that allow the biopharmaceutical industry to bring therapies to market more efficiently

Sang Kyu Lee, Representative Director - Avantor Korea/Japan (Left), James Hwang, Head of Application, Asia, Middle East & Africa – Biopharma after receiving the Awards for Best Company in Single-use Solutions and Upstream Processing at BMK 2022.
Incheon/New Delhi: Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences has been awarded as the best company in upstream processing and single-use solutions at the Biologics Manufacturing Korea (BMK) 2022 conference.
This is the second consecutive year that Avantor has been recognized for its upstream processing capabilities, a testament to its ongoing investment and innovations including development of high-purity raw materials, reagents and differentiated cell culture processes. In single-use solutions, Avantor received the best company award for the third consecutive year. Avantor was recognized for strengthening production capabilities and establishing an optimized supply chain in collaboration with global partners to respond to the growing need of biopharmaceutical manufacturers for single-use solutions.
Narayana Rao Rapolu, Vice President, Biopharma Asia Middle East & Africa for Avantor said, “Avantor’s single-use solutions enable biomanufacturers to bring new therapies to market faster and improve global health. Our local teams have expertise and experience across multiple processes that drive therapies forward from prototype development to system design, production and delivery. We offer the choice, agility and speed needed to support the evolving life-sciences market in Korea and across the region.”
Sang Kyu Lee, Representative Director for Avantor Korea & Japan said, “We are proud to be recognized for Avantor’s ability to support biopharmaceutical manufacturers through our comprehensive product portfolio and customer-driven production technologies. We continue to introduce innovations that allow life-changing therapies to reach the patients who need them.”